NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024

作者：Susan M. Swetter, Douglas B. Johnson, Mark R. Albertini, Christopher A. Barker, Sarah B. Bateni, Joel Baumgartner, Shailender Bhatia, Christopher K. Bichakjian, Genevieve M. Boland, Sunandana Chandra, Bartosz Chmielowski, Dominick J. DiMaio, Roxana Dronca, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Samantha Guild, John Hyngstrom, Giorgos C. Karakousis, Kari Kendra, Maija Kiuru, Julie R. Lange, Ryan M. Lanning, Theodore F. Logan, Daniel G. Olson, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, Luke D. Rothermel, April K.S. Salama, Rohit Sharma, Joseph J. Skitzki, Emily Smith, Katy K. Tsai, Evan Wuthrick, Yan Xing, Nicole R. McMillian, Sara Espinosa · 发表于：Journal of the National Comprehensive Cancer Network · 年份：2024 · DOI：10.6004/jnccn.2024.0036 · 被引用次数：149 · 研究领域：CAR-T cell therapy research、Cutaneous Melanoma Detection and Management、Melanoma and MAPK Pathways

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.